UCSF

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
星期四, 十一月 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
星期三, 十一月 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
星期四, 十一月 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

UCSF QBI and the Department of Psychiatry and Behavioral Sciences Announce Breakthrough Research Findings in the Molecular Understanding of Autism

Retrieved on: 
星期一, 十二月 4, 2023
Research, Neurology, Genetics, Clinical Trials, Biometrics, Biotechnology, General Health, Pharmaceutical, Health, Science, Sequence, ASD, Anatomy, School, Associate, Brain, Chemistry, Senior, Gladstone Institutes, Gene, Proteomics, Mass spectrometry, Quantitative Biosciences Institute, Spectrum, Protein, UCSF, Doctor of Philosophy, DSM-IV codes, Neuron, Psychiatry, University, Therapy, MD, Behavioural sciences, UCL, Neurogenesis, CRISPR, BioRxiv, SSD, Manuscript, QBI, Vaccine, Pharmacy, Neurosurgery

The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).

Key Points: 
  • The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).
  • Belinda Wang, MD, Ph.D., Rasika Vartak, Ph.D., Fima Zaltsman, Ph.D., and Zun Zar Chi Naing, Ph.D. are co-first authors of the manuscript.
  • Their findings provide unprecedented insights into the molecular mechanisms of a subset of individuals with ASD who carry specific genetic mutations, serving as a new platform for desperately needed therapeutics development.
  • QBI’s convergent biological systems approach that formed the basis of this study can be applied to virtually any disease area.

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

Retrieved on: 
星期二, 十一月 28, 2023
Software, Research, Radiology, Data Management, Technology, Medical Devices, Hospitals, Artificial Intelligence, Science, Biotechnology, FDA, Health, Other Science, Nurse practitioner, AMX, Physician, ICU, Google Images, UCSF, Multimedia, GE HealthCare, PTX, Intelligence, Diagnosis, AI, Triage, Critical care, DICOM, Medical imaging, PACS, Pneumothorax

Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX.

Key Points: 
  • Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX.
  • View the full release here: https://www.businesswire.com/news/home/20231128224829/en/
    On-device, CCS2.1 output from GE HealthCare's AMX Navigate mobile X-ray system showing PTX overlay and confidence level.
  • With this latest update, Critical Care Suite 2.1 provides immediate on-device detection and triage notifications for the presence or absence of pneumothorax (PTX).
  • By hosting Critical Care Suite on-device, critical insights are available at the point of care and across the entire clinical care team.

KBR Teams with HJF, Awarded Critical Contract to Aid Military Neuroscience Research

Retrieved on: 
星期一, 十二月 18, 2023
Research, NYSE, Military medicine, Force, Health, UCSF, NASA, HJF, Chronic traumatic encephalopathy, Therapy, Medical research, University, HHPC, Brain damage, Growth, Knowledge, Military personnel, CTE, Military, SPARC, Energy Savings Performance Contract, Education, KBR, Nursing, Family

HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.

Key Points: 
  • HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.
  • Research will be done in collaboration with the Uniformed Services University (the nation's only federal health sciences university), and the University of California San Francisco (UCSF).
  • Under the terms of the Service Personnel Advancing Research in Chronic Traumatic Encephalopathy (SPARC) contract, KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with chronic traumatic encephalopathy (CTE).
  • KBR also continues to collaborate with the Airmen Readiness and Medical Research (ARMR) contract on various brain scanning and neuroimaging projects.

Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models

Retrieved on: 
星期四, 十二月 14, 2023
ZINC, Terra Venture Partners, Partner (business rank), SAN, Therapy, UCSF, Inflammation, Doctor of Philosophy, Obesity, G protein-coupled receptor, DSM-IV codes, Stanford University, University, Drug discovery, Deep learning, ATP, GPCR, Fine chemical

SAN FRANCISCO and NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, today announced $52 million in Series A funding for its portfolio company Deep Apple Therapeutics, created and incubated by ATP to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries. With a powerful discovery engine that combines ensemble cryo-EM, deep learning, and molecular docking screens of ultra-large libraries, Deep Apple can go from target identification to lead optimization in less than 12 months – a fraction of the industry standard time – and can pursue biological target signaling inaccessible to conventional discovery approaches. Deep Apple's discovery engine is broadly applicable across disease areas and is particularly well-suited to expedited hit-finding against integral membrane proteins. The company currently is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.

Key Points: 
  • Deep Apple's discovery engine is broadly applicable across disease areas and is particularly well-suited to expedited hit-finding against integral membrane proteins.
  • "ATP created Deep Apple to revolutionize drug discovery in terms of speed, cost, and effectiveness," said Spiros Liras, Ph.D., founding CEO of Deep Apple and a Venture Partner at ATP.
  • And our virtual large-scale docking enables us to quickly home in on the right drug for the right target."
  • Wet-lab interrogations of the chosen virtual compounds feed back into the company's deep learning models to continually improve predictive performance.

The ACSR Democratizes Access To Pathology Data With Proscia, Advancing Breakthroughs For HIV Cancer Patients

Retrieved on: 
星期二, 十二月 12, 2023
Research, SAN, Pathology, National Cancer Institute, UCSF, Patient, Informatics, ACSR, HIV, Melanoma, Person, Cancer, Software, AIDS, Bangladesh Technical Education Board, News, Medical imaging, Biostatistics, PLWH, Epidemiology

SAN FRANCISCO and PHILADELPHIA, Dec. 12, 2023 /PRNewswire-PRWeb/ -- The AIDS and Cancer Specimen Resource (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) established in 1994 and funded by the National Institutes of Health, National Cancer Institute, is using software from Proscia®, a leading provider of digital and computational pathology solutions, to encourage scientific exploration and discovery in cancer in PLWH. Concentriq® for Research has enabled the ACSR to provide near real-time access to pathology data to investigators around the world.

Key Points: 
  • Concentriq® for Research has enabled the ACSR to provide near real-time access to pathology data to investigators around the world.
  • As digital pathology shifts the standard from microscope to high-resolution images, the ACSR recognized an opportunity to improve access to its data and drive further breakthroughs by adopting the technology.
  • Since selecting Concentriq for Research, the ACSR has reduced the time it takes to provide investigators with pathology data from days to hours.
  • "It enables breakthrough research with its pathology data and has meaningfully improved access to this critical source of insight with our platform.

Clipper® BayPass Welcomes Aboard UCSF as First Employer to Offer Workers Unlimited Free Transit

Retrieved on: 
星期五, 十二月 8, 2023
Metropolitan Transport Corporation (Chennai), Metropolitan Transit Commission, SAN, Policy, State university system, Student, UCSF, San Francisco State University, COVID-19, MTC, BART, University, Housing, Partnership, Muni, Travel, Airline, Renewable energy, San Francisco Bay Area

SAN FRANCISCO, Dec. 8, 2023 /PRNewswire/ -- The Metropolitan Transportation Commission and the University of California, San Francisco (UCSF) today finalized a partnership agreement through which UCSF will provide up to 6,000 of its employees with passes for unlimited free travel for one year on any of 24 Bay Area transit agencies beginning Jan. 1, 2024. The agreement, approved at the December meeting of MTCs Regional Network Management Committee, makes UCSF the first Bay Area employer to join Phase 2 of the Clipper® BayPass program, which is jointly managed by MTC and BART.

Key Points: 
  • UCSF's goal is to make public transit more accessible to employees in the university's lower salary tiers.
  • MTC teamed with BART and other transit agencies to launch Phase I of the Clipper BayPass pilot in August 2022.
  • Clipper BayPass partcipants used their passes for more than a combined 2 million transit trips in the first year of the pilot.
  • Transit agencies in 2024 will expand fare integration with the launch of a pilot program for no-cost and reduced-cost transfers between agencies.

$100M Saved in Drug Costs… And Growing

Retrieved on: 
星期三, 十一月 29, 2023
EHR, ROI, Doctor of Pharmacy, Pharmacist, UCSF, Patient, Pharmacy, Growth, Blue Shield, Prescription, Health care, Workflow, MD, Partnership, JAMA, Nursing, Pharmaceutical industry, Gemini

SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Gemini Health LLC, a California-based drug cost transparency platform company, announced today that it has surpassed $100M in drug cost savings in partnership with major health plans. The savings were generated over the past three years by identifying and delivering lower cost, high-quality drug and pharmacy alternatives for roughly half of all prescriptions - ten times the industry average. Alternatives and related savings are then sent to prescribers and pharmacists in workflow, as well as to members, via five patented Gemini services. Savings are identified in actual claims and are calculated based upon switches from higher cost drugs and pharmacies to lower cost alternatives that occur after a Gemini alternative was presented.

Key Points: 
  • SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Gemini Health LLC, a California-based drug cost transparency platform company, announced today that it has surpassed $100M in drug cost savings in partnership with major health plans.
  • The savings were generated over the past three years by identifying and delivering lower cost, high-quality drug and pharmacy alternatives for roughly half of all prescriptions - ten times the industry average.
  • Alternatives and related savings are then sent to prescribers and pharmacists in workflow, as well as to members, via five patented Gemini services.
  • The Business Group on Health recently released its annual survey of large employers, naming drug costs as a top concern.